Table 4
From the following article
Brazilian health biotech—fostering crosstalk between public and private sectors
Rahim Rezaie, Sarah E Frew, Stephen M Sammut, Maya R Maliakkal, Abdallah S Daar & Peter A Singer
Nature Biotechnology 26, 627 - 644 (2008)
doi:10.1038/nbt0608-627
Table 4. Collaborations/partnerships between firms interviewed and foreign entities
| Company | Alliances and their objectives |
|---|---|
| Aché Laboratórios Farmacêuticos | Partnerships: with Zeller (Romanshorn, Switzerland) for development of three phytomedicines; with Laboratorios Silanes (Mexico City) to market medicines in different countries; with University of Geneva (Switzerland) and University of Barcelona (Spain) for studies on plant extracts of clinical interest. Deal to distribute cosmetic products for Beiersdorf AG (Hamburg, Germany). Joint venture in planning stage with a foreign firm to construct a factory for the production of biotech-based medicines. |
| Biogene | Partnership with Fort Doge Animal Health (Kansas City, KS, USA) to develop a diagnostic test for leishmaniasis that can distinguish between leishmania-infected and vaccinated dogs, facilitating vaccination of dogs to prevent human transmission. |
| Biolab Sanus Farmacêutica | Collaboration with companies in Canada, Italy, Spain and Germany (details undisclosed). Co-marketing deal with AstraZeneca for Crestor (rosuvastatin). |
| BIOMM | Licensing agreement for tech-transfer and setup of a recombinant human insulin manufacturing facility with a company from Saudi Arabia. Collaborations with University of Halle (Germany) for protein purification and folding; with the University of Miami (Miami) to develop biomaterials and cell encapsulation technologies; with the University of Oulu (Finland) and the Shemyakin Research Institute (Moscow) for other activities; with equipment suppliers for equipment dimensioning and specification, process and equipment scale-up simulations. |
| COINFAR | Collaboration with US universities to advance safety and efficacy testing of lead molecules. |
| Cryopraxis Criobiologia | Collaborations with Interchem (Paramus, NJ, USA); with Saneron CCEL Therapeutics for development of clinical trials using umbilical cord blood; with the Texas Heart Institute (Houston) for the development of cell therapy procedures. |
| Eurofarma Laboratórios | Collaboration with Laboratorio Pablo Cassara (Buenos Aires) and Jurox (Rutherford, Australia). Joint venture with Edol Laboratory (Linda-a-Velha, Portugal) called Themaxis; In-licensing products from Almirall (Barcelona, Spain), Faes Farma (Madrid), Astellas Pharma (Tokyo), Bioderma (Lyon Cedex, France), CIMAB (Havana, Cuba) and DevaTal (Hamilton, NJ, USA) for technology transfer of recombinant Filgrastim and a number of other products. Co-development of a novel monoclonal antibody against EGFR for solid tumors with an international partner. |
| FK Biotecnologia | Partners in France for nanotechnology, in Canada for new immunotherapy diagnostics and in Korea for cell therapy. Deal to market in Brazil various products for Applichem (Darmstadt, Germany) and PARTEC (Munster, Germany). |
| Labtest Diagnóstica | Agreement with Tokyo Boeki (Tokyo) for supplying automatic analyzers. Collaboration with BioKit (Barcelona, Spain) to launch turbidimetric assays and ELISA products. |
| Nortec Química | Collaborations with Profarmaco (Milan) in joint-venture to manufacture active pharmaceutical ingredients (API); with Rhodia (Paris) to market and provide technical services for API. Deal with Albemarle (Richmond, VA, USA) to distribute an API in Brazil. Collaboration with World Health Organization (Geneva) resulting in export of anthelmintic diethylcarbamazine (anti-filariasis drug) and with the Clinton Foundation (Little Rock, AR, USA) to manufacture the HIV drug dideoxyinosine. |
| Silvestre Labs | Collaborations with Interchem (Paramus, NJ, USA) to help launch its Dermacerium and ExtraGraft products in the US; with the University of South Florida (Tampa, FL, USA) and Gamete Center at University of Michigan (Ann Arbor, MI, USA). |
